Skip to content

Acute respiratory distress syndrome comparative immune profiling

Acute respiratory distress syndrome patients with or without SARS CoV2 infection comparative immune profilng

Acute respiratory distress syndrome (ARDS) is the main complication of coronavirus disease 2019 (COVID-19), requiring admission to the intensive care unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, here, we build 3 cohorts of patients categorized in COVID-19ARDS+, COVID-19+ARDS+, and COVID-19+ARDS, and compare, by high-dimensional mass cytometry, their immune landscape. A cell signature associating S100A9/calprotectin-producing CD169+ monocytes, plasmablasts, and Th1 cells is found in COVID-19+ARDS+, unlike COVID-19ARDS+ patients. Moreover, this signature is essentially shared with COVID-19+ARDS patients, suggesting that severe COVID-19 patients, whether or not they experience ARDS, display similar immune profiles. We show an increase in CD14+HLA-DRlow and CD14lowCD16+ monocytes correlating to the occurrence of adverse events during the ICU stay. We demonstrate that COVID-19-associated ARDS displays a specific immune profile and may benefit from personalized therapy in addition to standard ARDS management. Read more: 

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

Recent News

Meet Scailyte at Immuno-Oncology 360° in New York, USA

Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at b...

Read more

Recent News

Inside Scailyte – Episode 5: Meet Daniel Schoener

Join us as we introduce you to Daniel Schoener, Executive Business Advisor at Scailyte AG. Daniel's ...

Read more

Recent News

ScaiDigest Volume 7: Unveiling Insights into Autoimmune Diseases

We're thrilled to share the latest installment of our ScaiDigest series, authored by our very own Di...

Read more

Recent News

Inside Scailyte – Episode 4: Meet Peter Evans

In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. ...

Read more

Recent News

Inside Scailyte – Episode 3: Meet Peter Nestorov

Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in th...

Read more

Recent News

Festival of Genomics 2024

Scailyte will be a part of the upcoming Festival of Genomics, on January 24th and 25th, 2024, in Lon...

Read more

Recent News

Inside Scailyte - Episode 2: Filipa Teixeira

We're back with another exciting episode of "Inside Scailyte," where we delve into the incredible jo...

Read more

Recent News

Single-cell omics and Al-fueled discovery to help endometriosis patients

Scailyte's powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaki...

Read more

Recent News

01 /04

Meet Scailyte at Immuno-Oncology 360° in New York, USA

Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at b...

Read more

Inside Scailyte – Episode 5: Meet Daniel Schoener

Join us as we introduce you to Daniel Schoener, Executive Business Advisor at Scailyte AG. Daniel's ...

Read more

Recent News

02 /04

ScaiDigest Volume 7: Unveiling Insights into Autoimmune Diseases

We're thrilled to share the latest installment of our ScaiDigest series, authored by our very own Di...

Read more

Inside Scailyte – Episode 4: Meet Peter Evans

In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. ...

Read more

Recent News

03 /04

Inside Scailyte – Episode 3: Meet Peter Nestorov

Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in th...

Read more

Festival of Genomics 2024

Scailyte will be a part of the upcoming Festival of Genomics, on January 24th and 25th, 2024, in Lon...

Read more

Recent News

04 /04

Inside Scailyte - Episode 2: Filipa Teixeira

We're back with another exciting episode of "Inside Scailyte," where we delve into the incredible jo...

Read more

Single-cell omics and Al-fueled discovery to help endometriosis patients

Scailyte's powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaki...

Read more

Recent News